Comparative Pharmacology
Head-to-head clinical analysis: NORGESTREL AND ETHINYL ESTRADIOL versus OGEN 5.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NORGESTREL AND ETHINYL ESTRADIOL versus OGEN 5.
NORGESTREL AND ETHINYL ESTRADIOL vs OGEN 5
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Norgestrel is a progestogen that suppresses gonadotropin secretion, primarily LH, inhibiting ovulation and altering cervical mucus to impede sperm penetration. Ethinyl estradiol is an estrogen that stabilizes the endometrium and provides negative feedback on gonadotropin release, contributing to contraceptive efficacy.
Estrogen replacement; binds to estrogen receptors, activating gene transcription for estrogenic effects in target tissues.
One tablet (0.3 mg norgestrel/0.03 mg ethinyl estradiol) orally once daily, taken at the same time each day.
0.625 mg orally once daily, adjusted based on response.
None Documented
None Documented
Norgestrel: terminal half-life ~45 hours (range 24–50 h), supporting once-daily dosing; Ethinyl estradiol: terminal half-life ~17 hours (range 10–24 h).
Terminal elimination half-life of estrone (primary active metabolite) is approximately 20 hours; steady-state concentrations achieved within 6-8 days. Half-life of estradiol is shorter (1-2 hours) but clinically the estrogenic effect correlates with estrone.
Norgestrel: 45% renal, 32% fecal as metabolites; Ethinyl estradiol: 40% renal, 60% fecal as glucuronide and sulfate conjugates.
Renal (primarily as conjugated metabolites); approximately 50-80% of an oral dose is excreted in urine, with about 20% in feces via biliary elimination.
Category D/X
Category C
Estrogen
Estrogen